Literature DB >> 8253998

Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.

D J Biedenbach1, R N Jones, M E Erwin.   

Abstract

Eight newer orally administered cephems (cefdinir, cefetamet, cefixime, cefpodoxime, cefprozil, ceftibuten, cefuroxime, and loracarbef) were tested against 100 clinical strains of Morganella morganii to determine the extent of serious interpretive very major (false-susceptible) errors when current criteria for the disk diffusion test are applied. Agar dilution MICs and disk diffusion tests were performed as recommended by the National Committee for Clinical Laboratory Standards (Villanova, Pa.) (NCCLS), and the methods were compared by regression analysis using the method of least squares and by error rate bounding. The following results are listed in the order of increasing error rates: cefdinir, loracarbef, and cefprozil, < or = 1% very major error; ceftibuten, 8% minor errors; cefuroxime, 21% minor errors; cefixime, cefpodoxime, and cefetamet, very major errors of 15, 24, and 36%, respectively. M. morganii produces unacceptable rates of test error with cefuroxime, cefixime, cefpodoxime, and cefetamet. The latter two cephalosporins currently have NCCLS table footnote warnings covering the problem observed with this organism. The inclusion of cefuroxime and cefixime in the NCCLS table footnote is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253998      PMCID: PMC266029          DOI: 10.1128/jcm.31.10.2828-2830.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.

Authors:  R N Jones; M E Erwin; B B Gooding
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

3.  Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

4.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  In vitro antibacterial activity of FK482, a new orally active cephalosporin.

Authors:  Y Mine; T Kamimura; Y Watanabe; S Tawara; Y Matsumoto; F Shibayama; H Kikuchi; T Takaya; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1988-12       Impact factor: 2.649

6.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Am J Clin Pathol       Date:  1983-08       Impact factor: 2.493

8.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Cefixime disk susceptibility test criteria.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

10.  Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

View more
  3 in total

Review 1.  Classification, identification, and clinical significance of Proteus, Providencia, and Morganella.

Authors:  C M O'Hara; F W Brenner; J M Miller
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.

Authors:  D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

3.  Poor efficacy of preemptive amoxicillin clavulanate for preventing secondary infection from Bothrops snakebites in the Brazilian Amazon: A randomized controlled clinical trial.

Authors:  Jacqueline A G Sachett; Iran Mendonça da Silva; Eliane Campos Alves; Sâmella S Oliveira; Vanderson S Sampaio; Fábio Francesconi do Vale; Gustavo Adolfo Sierra Romero; Marcelo Cordeiro Dos Santos; Hedylamar Oliveira Marques; Mônica Colombini; Ana Maria Moura da Silva; Fan Hui Wen; Marcus V G Lacerda; Wuelton M Monteiro; Luiz C L Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2017-07-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.